TickerTalks
Browse all tickers →
TickerTalks›$INDP
ININDP

Indaptus Therapeutics, Inc.

$INDP·$284M·Biotechnology·Healthcare
$2.85+29.0%YTD-18.7%1Y-26.5%
Price updated 8h ago·X counts updated 4d ago
ININDP
$INDPIndaptus Therapeutics, Inc.
$2.85+28.96%53 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $INDP on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

53X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $INDP's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 87% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $INDP — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellStalledAI verdict · as of 2026-10-03

The move has stalled — likely just drifts unless something new shows up.

Indaptus is a pre-clinical immunotherapy biotech at $270M market cap with a fresh $24M raise and a $100M ATM upsize — pure optionality.

Indaptus Therapeutics is a pre-clinical biotech developing an immunotherapy platform using engineered bacterial fragments — anti-cancer, anti-viral, and auto-immune applications. The stock has lost 19% YTD with zero revenue and multiple capital raises.

  • Revenue is zero: four quarters at zero with Q1 2026 EPS of -$1.17 and Q4 2025 EPS of -$3.74 — this is pre-clinical economics where the entire valuation is binary on IND-enabling data and future clinical trial readouts.
  • The capital raises are stacking: a $24M private placement on Sep 10 plus a $100M H.C. Wainwright ATM upsize on Sep 8 — the equity line is being used aggressively, which supports the current burn but dilutes with every move higher.
  • There's no near-term operational catalyst visible: no scheduled IND or Phase 1 readouts in the sample, with Nov 17 earnings as the next cash-runway update.

An IND filing or a signed strategic partnership restarts the thesis; another capital raise before scientific data and the stock drifts further on dilution risk.

What to watch: Nov 17 Q3 earnings — cash runway, IND-enabling data timelines, any new strategic-partner disclosures, and the pace of ATM issuance. A credible IND filing re-rates it; another dilutive raise without data and the stock drifts.

On the calendar: 2026-11-17 — Q3 2026 earnings

Read the AI verdict on $INDP

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Indaptus Therapeutics is a pre-clinical biotech developing a multi-pathway innate immune activator for cancer immunotherapy.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $INDP.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $INDP

Neutral — Indaptus Therapeutics is a pre-clinical biotech developing a multi-pathway innate immune activator for cancer immunotherapy.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-130%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-9.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-303%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.02$-0.02-27.4%
Q1 2026May 15, 2026$-0.23$-1.87+87.7%
Q4 2025Mar 17, 2026$-3.10$-4.36+28.9%
Q3 2025Nov 12, 2025$-2.98$-4.17+28.5%
Next earningsTue, Nov 17·consensus EPS $-1.46

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.02$-1.9M
Q1 FY26$0———$-1.17$-7.0M
Q4 FY25$0———$-3.74$-3.2M
Q3 FY25$0———$-0.52$-3.1M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$6.34-$6.34 – -$6.340
FY27$0$0 – $0-$4.42-$4.42 – -$4.420
FY28$42.4M$42.4M – $42.4M$0.79$0.79 – $0.791
FY29$123.0M$123.0M – $123.0M$6.40$6.40 – $6.401

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.38%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+35.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+25.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β1.175-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementSep 308-K — Item 1.01: Material agreement
8-KMaterial agreementSep 108-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale
AI summary

Indaptus Therapeutics completed a private placement of approximately 20.339 million shares at Nasdaq Minimum Price plus $0.015 per share, raising approximately $24 million in gross proceeds. Proceeds will be used for working capital, R&D, and potentially a neurotechnology sleep device — a new indication suggesting pipeline diversification beyond oncology. The capital injection provides near-term funding runway for the small biotech.

8-K/AMaterial agreement (amended)Sep 88-K/A — Item 1.01: Material agreement
AI summary

Indaptus Therapeutics (INDP) amended and restated its at-the-market equity offering agreement with H.C. Wainwright to allow the sale of up to $100 million in common stock, updating the June 2022 original agreement. The ATM facility provides ongoing equity capital access without requiring fixed-size underwritten offerings.

8-KOfficer or director changeSep 48-K — Item 5.02: Officer or director change
AI summary

Tim Ruan resigned from the board of directors of Indaptus Therapeutics (INDP) effective immediately on September 2, 2026, citing no disagreement with the company's operations, policies, or practices. The resignation is not related to any dispute with management.

424B5Prospectus supplement (offering)Sep 4424B5
AI summary

Indaptus Therapeutics (INDP) filed Amendment No. 1 to its prospectus supplement for an at-the-market offering of up to $100 million in common stock, amending the August 31, 2026 prior supplement. The amendment updates or corrects information in the prior supplement as part of the ongoing ATM program.

8-KMaterial agreementSep 18-K — Item 1.01: Material agreement
AI summary

Indaptus Therapeutics, Inc. entered into an Amended and Restated At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co. on August 28, 2026, replacing the original June 2022 agreement. The amended agreement enables Indaptus to sell up to $100 million in shares of its common stock from time to time through H.C. Wainwright as sales agent or principal. This provides the company with an updated and expanded capital-raising facility for future financing needs. The full amended agreement is filed as an exhibit to the 8-K.

424B5Prospectus supplement (offering)Aug 31424B5
AI summary

Indaptus Therapeutics, Inc. filed a prospectus supplement on Form 424B5 for an at-the-market (ATM) offering of up to $100 million in common stock, with H.C. Wainwright & Co. acting as sales agent or principal pursuant to the Amended and Restated ATM Offering Agreement dated August 28, 2026. Prior sales under predecessor agreements totaled approximately $2.74 million in aggregate proceeds. The prospectus supplement enables Indaptus to raise capital on a flexible, ongoing basis through market sales. This filing completes the disclosure package for the updated ATM facility.

S-3Shelf registrationAug 17S-3
AI summary

Indaptus Therapeutics (INDP) filed a new Form S-3 shelf registration statement on August 17, 2026, registering securities for delayed or continuous offering under Rule 415; Junyi Dai serves as CEO and is listed as the registrant contact. The total securities amount and security types are not visible in the excerpt. This is the second S-3 filing by Indaptus in 2026 (the first was filed June 26, 2026), providing ongoing capital raising flexibility amid significant ownership concentration from the March 2026 financing.

+ 20 other (5 8-Ks · 5 SC 13D/As · 2 EFFECTs · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com·64d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $INDP on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport